Identification of Deferasirox as a Potential Carbonic Anhydrase II Inhibitor for Glaucoma treatment via Virtual Screening
نویسندگان
doi
10.22037/joos.v6i1.42856چکیده
Background: Systemic or topical administration of sulfonamide-containing carbonic anhydrase (CA) inhibitors is currently one of the lowering IOP approaches to treat glaucoma. Carbonic anhydrase II is an eye-expressed CA isoenzyme and has a major role in aqueous humor production.